Basolateral efflux clearance (CL BL ) contributes significantly to rosuvastatin (RSV) elimination in sandwich-cultured hepatocytes (SCH). 
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Introduction
The role of hepatic transport in the pharmacokinetics and pharmacodynamics of rosuvastatin (RSV) has long been recognized (Nezasa et al., 2002; Ho et al., 2006; Zhang et al., 2006; Kitamura et al., 2008) . Mechanisms mediating hepatic uptake (OATPs, NTCP) and biliary excretion (MRP2, BCRP) have been well-characterized (Ho et al., 2006; Huang et al., 2006; Zhang et al., 2006; Kitamura et al., 2008; Keskitalo et al., 2009; Hobbs et al., 2012) . Recently, it was shown that basolateral efflux represents a significant elimination route from rat and human hepatocytes using a novel uptake/efflux protocol in sandwich-cultured hepatocytes (SCH) (Pfeifer, 2013) . Of the candidate transport proteins known to mediate hepatic basolateral efflux of drugs and metabolites, RSV was shown to be a substrate of human MRP4 (Pfeifer, 2013) , which likely contributes to the basolateral efflux of RSV in human liver.
The importance of hepatic basolateral efflux in drug disposition remains largely unrecognized except in the case of hepatically-derived drug conjugates (Zamek-Gliszczynski et al., 2006; Hardwick et al., 2012) . Exceptions include fexofenadine (Tian et al., 2008) , enalaprilat (de Lannoy et al., 1993) and methotrexate (Vlaming et al., 2009 ). As such, availability of tools and information for prediction and in vitro-in vivo extrapolation (IVIVE) of hepatic basolateral efflux lags behind the development of these tools for more-recognized pathways such as hepatic uptake and biliary excretion. Although isolated expression systems have been employed for some proteins known to facilitate hepatic basolateral efflux, such as Mrp3/MRP3 and Mrp4/MRP4 (Hirohashi et al., 1999; Akita et al., 2002; Chen et al., 2002) , other JPET #208314 bile) was decreased without a significant increase in RSV liver concentrations, while systemic exposure was increased more than 3-fold (Kitamura et al., 2008) . While this may suggest efficient hepatic basolateral efflux of RSV in the setting of impaired biliary excretion, decreased hepatic uptake and/or impaired renal elimination in EHBR rats may contribute to the increased systemic exposure. An important advantage of the IPL model is that the role of hepatic processes can be evaluated in isolation from other organ systems (Brouwer and Thurman, 1996) . RSV disposition was reported recently in recirculating isolated perfused livers (IPLs) from WT and Mrp2-deficient (TR -) rats (Hobbs et al., 2012) .
Increased perfusate concentrations in TR -compared to WT livers were attributed to decreased hepatic uptake, however, the role of basolateral excretion was not considered. The single-pass IPL system used in the present study allowed for direct evaluation of basolateral excretion from liver to perfusate.
RSV is not metabolized extensively in humans; identified metabolites include the inactive 5S-lactone, as well as N-desmethyl-RSV, which is formed by Cytochrome P450 2C9 (CYP2C9) and retains up to 50% of the HMG-CoA-reductase inhibitor activity of RSV (Martin et al., 2003b) . Although metabolism plays a similarly minor role in rats in terms of overall mass balance, metabolites have been reported to account for a significant portion (~50%) of plasma and liver content in whole animal studies (Nezasa et al., 2002; Kitamura et al., 2008) . Biotransformation of RSV in rats is mediated primarily by β-oxidation of the fatty acid chain, with no evidence of CYP involvement. The pentanoic acid derivative (RSV-PA) has been suggested as the primary metabolite based on thin-layer chromatography of extracted plasma and liver samples from rats administered [
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drug interactions (DDIs) and genetic polymorphisms has been shown to alter the pharmacokinetics of RSV (Schneck et al., 2004; Simonson et al., 2004; Zhang et al., 2006; Kiser et al., 2008; Keskitalo et al., 2009 ). Some of these changes have been associated with altered efficacy (LDL-lowering) of RSV (Simonson et al., 2003; Tomlinson et al., 2010) , while increased systemic exposure has been associated with life-threatening rhabdomyolysis related to statin use in general (Hamilton-Craig, 2001; Thompson et al., 2003) .
The present experiments were designed to quantify the contribution of the basolateral efflux pathway to the hepatocellular elimination of RSV in single-pass rat IPLs. In addition, clearance values generated using a novel uptake/efflux protocol that was developed in the SCH model were compared to this dataset generated in whole liver. IPL data, combined with pharmacokinetic modeling, revealed that basolateral efflux represents a significant route of RSV hepatocellular excretion from rat liver, similar to findings in SCH. In addition, reduced CL BL and CL Bile of RSV in TR -livers highlighted the contribution of biotransformation as an alternative elimination pathway in the setting of impaired hepatic efflux in rat liver, with the pentanoic acid derivative of RSV (RSV-PA) identified as the primary metabolite.
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Materials and Methods
Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. RSV and the deuterated internal standard (d 6 -RSV) were purchased from Moravek Biochemicals (Brea, CA).
GF120918 (elacridar) was a generous gift from GlaxoSmithKline (Research Triangle Park, NC). Hill, NC). All procedures were performed under full anesthesia with ketamine/xylazine (140/8 mg/kg i.p.).
Animals
Isolated Perfused Livers (IPLs)
WT and TR -rat livers were perfused in a single-pass manner as described previously (Brouwer and Thurman, 1996; Chandra et al., 2005) . Briefly, following cannulation of the portal vein and bile duct, livers were perfused in situ with continuously-oxygenated Krebs-Ringer bicarbonate buffer (35 mL/min) containing 5 μM taurocholate to maintain bile flow. Livers were removed from the body cavity and placed in a humidified perfusion chamber heated to maintain liver temperature at 37°C. Perfusion was continued for a 15-min equilibration period, and then switched to a RSV-containing perfusate (0.5 μM)
for the 60-min loading phase; at 60 min, the buffer was switched to RSV-free perfusate, and perfusion was continued for an additional 30 min. For conditions in the presence of inhibitor, the perfusate also contained 0.5 μM GF120918 for the duration of the experiment (15-min equilibration period followed by the 90-min perfusion; Fig 1) . This concentration was sufficient to inhibit RSV biliary excretion in TR -SCH with minimal impact on uptake (Pfeifer, 2013) . Liver viability was assessed by monitoring inflow perfusion pressure (<15 mm H 2 O), gross morphology, and maintenance of bile flow (within 30% of the baseline rate during the equilibration period). Bile and perfusate were collected over 5-min intervals, and bile volume was determined gravimetrically in pre-weighed tubes. After perfusion, livers were blotted dry, weighed, and stored at -80°C until analysis.
Bioanalysis
RSV was quantified by LC-MS/MS as described previously for samples derived from IPL studies (Abe et al., 2008) . RSV-PA was identified by high resolution LC-MS/MS (TOF/TOF) using an ABSciex 5600 TripleTOF mass spectrometer (Fig. 2) . Direct absolute quantification of RSV-PA was not possible due to the lack of an analytical standard. However, estimating sample-to-sample difference in the relative concentrations of RSV-PA was possible by comparing normalized peak area ratios (RSV-PA:d6-RSV internal standard). The absolute concentration of RSV-PA was estimated from normalized peak area ratios (RSV-PA:d6-RSV internal standard) by the calibration curve generated using the peak area ratios (RSV-PA:d6-RSV internal standard) of samples with known concentrations of RSV, with the assumption that RSV and RSV-PA have similar ionization efficiencies.
Pharmacokinetic Modeling
Pharmacokinetic modeling and simulation were used to evaluate RSV disposition in rat IPLs, and to determine the effects of GF120918 and loss of Mrp2 function on RSV hepatobiliary disposition.
Models incorporating various combinations of linear and/or non-linear parameters governing RSV flux were fit to rate versus time data from individual experiments (Fig. 3) 
where variables and parameters are defined as in Fig. 3 with further explanation as follows. C EC,n is the extracellular concentration, calculated as X EC,n /(V EC /5) and V EC is the extracellular volume of the liver, which was assumed to be in equilibration with the sinusoidal space and estimated at 20% of the total liver mass, as reported previously (Watanabe et al., 2009; Hobbs et al., 2012) . Q is the perfusate flow rate of was determined by equilibrium dialysis with an unbound fraction of 0.25, corrected for dilution. The total intracellular liver concentration was calculated as the sum of the mass in liver subcompartments 1-5, divided by the intracellular volume (V L ), calculated as total liver mass minus the V EC . The RSV concentration resulting in half-maximal biliary excretion (K m ) was set to 10 μM based on the reported affinity of RSV for Mrp2 and Bcrp in isolated expression systems (Huang et al., 2006; Deng et al., 2008) .
The C EC,5 ×Q was fit to the observed appearance rate in outflow perfusate, while the sum of the excretion rate in bile (dX Bile,n /dt) for liver subcompartments 1-5 was fit to the observed biliary excretion rate. The sum of the RSV and RSV-PA mass in liver subcompartments 1-5 was fit to observed recovery of RSV and RSV-PA in liver tissue at the end of the study. Initial parameter estimates were obtained from a combination of direct extrapolation of IPL data and simulations in Berkeley-Madonna. V max was estimated initially as the steady-state excretion rate in bile since the unbound liver concentrations were estimated from mass balance to be ~3-5 times the K m for the biliary excretion process. Rapid attainment of steady-state in the outflow perfusate of WT IPLs precluded accurate estimation of the CL Uptake .
Therefore, CL Uptake was fixed at 40 mL/min/g liver based on two independent reports of RSV initial uptake (determined at timepoints <1 min) in freshly-isolated, suspended WT rat hepatocytes (Nezasa et al., 2003; Yabe et al., 2011) , using standard conversion factors of 200 mg protein/g liver and 100 million cells/g liver (Swift et al., 2010) . Metabolic clearance to the pentanoic acid derivative (CL Met ) and other potential metabolites (CL Other ) were estimated initially from simulations in Berkeley-Madonna.
Transporter-mediated clearance values [CL Uptake , CL BL and CL Bile (V max /K m in the linear range e )]
estimated from pharmacokinetic modeling of RSV IPL data were compared to analogous parameter values reported previously in rat SCH (Pfeifer, 2013) ; scaling factors were reported for the WT Control conditions. Scaling factors represent the respective clearance value in the IPL divided by the corresponding value in SCH.
Data Analysis
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 4A) , while the addition of GF120918 in TR -livers markedly reduced the biliary excretion rate of RSV (Fig. 4B) . Interestingly, the initial appearance rate of RSV in the outflow perfusate was reduced in TR -compared to WT livers (Fig 4C and D) . Addition of GF120918 slightly reduced the rate of RSV appearance in outflow perfusate of WT livers (Fig. 4C ), but had no effect on the rate of RSV appearance in outflow perfusate of TR -livers (Fig. 4D) . The cumulative recovery of RSV in perfusate over the 90-min study tended to be reduced in TR -compared to WT livers in the absence of GF120918, and also by GF120918 in WT livers (Fig. 5) ; however, the individual effects of Mrp2 status (WT vs. TR   -) and GF120918 failed to reach significance after correcting for multiple comparisons. Biliary recovery of RSV was not affected significantly by GF120918 in WT IPLs, but the effect of GF120918 on the reduced biliary recovery in TR -IPLs was statistically significant (Fig. 5 ). The effect of Mrp2 status on RSV biliary recovery was statistically significant in the presence of GF120918, but not in the absence of GF120918 ( The presence of the pentanoic acid metabolite of RSV (RSV-PA) was confirmed by both targeted and untargeted high resolution LC-MS/MS. The targeted approach was based on a previous report that suggested that RSV-PA was the primary metabolite in rat (Nezasa et al., 2002) . First, targeted extracted ion chromatograms (422.20±0.05 amu) from full-scan TOF revealed this parent ion was only present in samples from RSV-perfused livers ( Fig. 2A) . Second, comparisons between the high-resolution product ion spectra of RSV (482.20 amu) and the 422.20 amu parent ion further substantiated this unique analyte to be RSV-PA (Fig. 2B ). Using the proposed structure for the metabolite, there were common product ions formed (242.10, 256.12 and 270.17 amu; Fig. 2B ), which were independent of the changes within the carboxylic acid side chain. Additionally, the paired product ions, 402. representing <2% of the total dose over the course of the study. As such, RSV-PA was reported only in the liver tissue (Fig. 5) . RSV-PA comprised approximately 40% of total RSV content (metabolite:parent ratio of 0.70±0.24 and 0.70±0.30 in the absence and presence of GF120918, respectively) in TR -liver tissue, or 16% of the total administered dose of RSV at the end of the perfusion (Fig. 5) . In contrast, while RSV-PA accounted for a similar proportion of total RSV content in WT liver tissue at the end of the perfusion (~30%; metabolite:parent ratio of 0.58±0.28 and 0.50±0.10 in the absence and presence of GF120918, respectively), this comprised only ~3% of the total administered dose of RSV (Fig. 5) .
Parameter estimates recovered from fitting the differential equations based on the model scheme depicted in Fig. 3 to the data are listed in 
Discussion
The present perfused liver studies confirm a significant role for basolateral efflux in the hepatobiliary disposition of RSV in rat hepatocytes, as recently demonstrated in rat SCH (Pfeifer, 2013) .
The effects of modulating Mrp2 and Bcrp function using TR -rat livers and GF120918, respectively, were consistent with SCH data and previous reports suggesting that each transporter contributes to a similar degree, and together comprise approximately 90-95% of RSV biliary excretion in rats (Table 1) ( Kitamura et al., 2008; Hobbs et al., 2012; Pfeifer, 2013 (Chen et al., 2003) . APAP-GSH and RSV likely compete for basolateral excretion with GSH and other organic anions that accumulate in TR -livers due to the absence of Mrp2 (Elferink et al., 1989) . Similar to recent data reported by our group for RSV (Pfeifer, 2013) , GSH and GSH conjugates are poor substrates for Mrp3, with basolateral excretion mediated primarily by Mrp4 decrease, respectively, in rat SCH compared to liver tissue (Li et al., 2009; Li et al., 2010) . Therefore, the effects of these changes appear to have a minimal impact on RSV CL Bile .
Following i.v. administration of RSV to healthy humans, approximately 72% of the dose was eliminated by the liver, with an estimated hepatic extraction (E h ) of 0.63 (Martin et al., 2003a a result of basolateral efflux. This is evident from the low initial appearance rate of RSV in outflow perfusate, especially from the TR -IPLs, and the absence of a "drop-off" in the outflow perfusate profile when the RSV-containing inflow perfusate was switched to blank buffer at 30 min, thereby initiating the efflux phase in single-pass IPL studies ( Fig. 4C and D) (Akita et al., 2001; Chandra et al., 2005 ). These studies demonstrate for the first time the important role of hepatic basolateral efflux in mediating systemic RSV exposure, including impairment of this efflux pathway in TR -compared to WT IPLs.
In the present studies, the addition of GF120918 nearly ablated RSV CL Bile in TR -livers, with minimal effects on accumulation and CL Bile in WT livers. This finding was expected based on the fraction excreted (f e ) concept (Zamek-Gliszczynski et al., 2009) , which states that loss-of-function of a transport pathway associated with f e <0.5 will have minor consequences on excretion and tissue exposure; in contrast, exposure will change exponentially in response to loss-of-function of transport pathways with f e >0.5. RSV is excreted into rat bile by Bcrp and Mrp2. In WT rat livers, GF120918 appeared to impair <50% of RSV CL Bile , which resulted in minimal changes in accumulation and biliary recovery of RSV. In contrast, in TR -livers lacking Mrp2, the addition of GF120918 resulted in ≥90% impairment of RSV CL Bile , which appeared to be greater than proportional based on the loss of Mrp2 (TR -livers) and Bcrp (GF120918) function in isolation; however, this effect is well-established (Zamek-Gliszczynski et al.,
2009).
Interestingly, in a whole animal study with WT Sprague-Dawley and Mrp2-deficient Eisai hyperbilirubinemic rats (EHBR), liver concentrations of RSV were not increased significantly in EHBR animals, as measured by total radioactivity with separation of metabolites by thin-layer chromatography (Kitamura et al., 2008) . RSV disposition also was reported recently in recirculating perfused WT and TR -IPLs using LC-MS/MS detection (Hobbs et al., 2012) . Increased liver accumulation was observed in TR -compared to WT IPLs, similar to the present study, however, the roles of metabolism and/or basolateral excretion were not considered. The present studies suggest that impaired CL BL , as well as CL Bile , contributes to the increased hepatic exposure of RSV in TR -compared to WT rat livers.
Results of the present study confirmed the presence of RSV-PA as the primary metabolite, contributing ~30-40% of total RSV content in both WT and TR -livers following the 30-min efflux period, consistent with previous reports in whole animals (Nezasa et al., 2002; Kitamura et al., 2008) .
Delayed elimination of RSV metabolites, including RSV-PA, also is consistent with data in whole animals (Nezasa et al., 2002) . Measurement of total radioactivity in previous SCH experiments precluded comparisons of RSV-PA formation between IPL and in vitro studies. However, the increase in hepatic accumulation of RSV and RSV-PA in TR -compared to WT IPLs is consistent with impaired RSV excretion and "shunting" to the metabolic pathway(s).
Tools and information remain scarce to help predict the consequences of altered function of hepatic basolateral efflux mechanisms. Quantitative proteomics data and substrate/inhibitor specificity for transport proteins mediating hepatic basolateral efflux lag behind availability of such information for hepatic uptake and biliary excretion pathways. For example, quantitative proteomics data for MRP3 and MRP4 in whole liver and isolated hepatocytes has become available only recently and is exclusive to humans. Additionally, the data is based on a minimal number of samples compared to data for other transporters (Ohtsuki et al., 2012; Schaefer et al., 2012) . Similarly, screening for substrates and inhibitors of MRP3 and MRP4 is extremely limited compared to other hepatic transporters (Koeck et al., 2012; Sedykh et al., 2012) . The number and role of precise proteins involved in basolateral efflux remains to be elucidated. OATPs have been reported to function in a bidirectional manner (Li et al., 2000; Mahagita et al., 2007) , while emerging transporters include the organic solute transporter (OST) α/β, which is localized to the basolateral membrane of the entero-and hepatocytes, serves as a bidirectional transporter of bile acids between cells and blood (Ballatori et al., 2005) and has been postulated to transport RSV in Caco-2 cells (Li et al., 2012) . Given the limitations of current knowledge, it is important to assess the basolateral efflux of RSV and other drugs in whole liver in order to ascertain the potential role of this pathway in vivo.
This article has not been copyedited and formatted. The final version may differ from this version. Based on the present studies, impaired basolateral efflux clearly has the potential to impact hepatic and systemic exposure of RSV, and shift routes of elimination through interplay between transport and metabolism. Although the importance of hepatic basolateral efflux has long been recognized for phase II conjugates, this work demonstrates the significance of this pathway in disposition of the parent drug, RSV. Increasing recognition of the contribution of hepatic basolateral efflux transporters to systemic and hepatic exposure of drugs/metabolites highlights the need to evaluate the consequences of altered function of these transport proteins due to DDIs, genetic variation and/or disease on drug disposition, which may ultimately impact the efficacy and/or toxicity of medications that are substrates for these transporters.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 4.2 ± 1.7 85 ± 27 Mean ± SD (n=3 livers) CL Uptake was fixed at 40 mL/min/g liver (Nezasa et al., 2003; Yabe et al., 2011 The simulated excretion rate-time profiles were generated from the relevant equations based on the model scheme in Figure 3 and the final parameter estimates reported in Table 1 . Gray arrow indicates the switch from RSV-containing to RSV-free perfusate at 60 min. Data are presented as mean±SD (n=3 livers). 
